Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Bilthoven – page 83

1 718 clinical trials in Bilthoven, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Bilthoven at a glance
1 718
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

1 718 trials in Bilthoven

Open in trial search

Malignant melanoma

Not recruiting

Study of Acasunlimab Alone and Combined With Pembrolizumab in Patients With Advanced Skin Melanoma That Returned or Did Not Respond to Prior Treatment

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Immune thrombocytopenia

Not recruiting

A Study of Ianalumab and Eltrombopag for Patients with Primary Immune Thrombocytopenia Who Did Not Respond Well to or Relapsed After Steroid Treatment

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Eltrombopag
  • Sponsor:Novartis Pharma AG

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Acute myocardial infarction

Not recruiting

A study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Not recruiting

Study of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Food allergy

Not recruiting

Study of DBV712 skin patch safety in children aged 1-3 years with peanut allergy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Water For Injection
  • Sponsor:Dbv Technologies

Non-small cell lung cancer

Not recruiting

Study of zoldonrasib in patients with RAS G12D mutation non-small cell lung cancer who have received previous treatment

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Revolution Medicines Inc.

Pneumococcal immunisation

Not recruiting

Study of 20-valent pneumococcal conjugate vaccine (PCV20) booster response in healthy adults aged 78-84 years

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years · Healthy volunteers
  • Sponsor:Rijksinstituut voor Volksgezondheid en Milieu (RIVM)

Retinitis pigmentosa

Not recruiting

Study of ultevursen treatment in patients with retinitis pigmentosa caused by mutations in USH2A gene exon 13

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ultevursen
  • Sponsor:Laboratoires Thea

Fabry's disease

Not recruiting

Study comparing venglustat tablets with standard therapy for adult patients with Fabry disease and left ventricular hypertrophy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Agalsidase beta
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm

Not recruiting

Long-term study of dabrafenib and trametinib in children and adolescents with cancers that have V600 mutation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Dabrafenib Mesylate
  • Sponsor:Novartis Pharma AG

Duchenne muscular dystrophy

Not recruiting

Study of BMN 351 given by intravenous infusion to evaluate safety and tolerability in patients with Duchenne Muscular Dystrophy

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:BMN 351
  • Sponsor:Biomarin Pharmaceutical Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Bilthoven

What the registry says about research in the country

01 Infectious Disease Prevention

Research focusing on optimizing vaccine effectiveness against multiple infectious diseases, including studies on meningococcal disease and influenza in different age groups.

  • Meningococcal Disease Prevention
  • Influenza Vaccination Timing
  • Early Measles Protection

Novel approaches include investigating optimal vaccination timing and early immunization strategies for enhanced protection.

02 Oncology Research

Advanced studies in breast cancer treatment, examining innovative therapeutic combinations for hormone receptor-positive cases.

  • Hormone Receptor Positive Breast Cancer
  • CDK 4/6 Inhibition Therapy
  • Sequential Treatment Strategies

Investigations focus on optimizing treatment sequences to improve progression-free survival rates.

03 Surgical Interventions

Clinical research examining surgical treatments combined with antibiotic therapy for improved patient outcomes.

  • Perianal Abscess Management
  • Combined Treatment Approaches
  • Fistula Prevention

Studies aim to enhance surgical outcomes through innovative combination therapies.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.